Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 6/20 | 0.84 |
| ▸ | HTR2C | P28335 | 5/20 | 0.84 |
| ▸ | DRD1 | P21728 | 4/20 | 0.84 |
| ▸ | HRH1 | P35367 | 4/20 | 0.84 |
| ▸ | HTR2A | P28223 | 4/20 | 0.84 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.84 |
| ▸ | DRD2 | P14416 | 2/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.84 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.84 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.69 |
| ▸ | HTR1D | P28221 | 4/20 | 0.69 |
| ▸ | HTR7 | P34969 | 4/20 | 0.69 |
| ▸ | DRD4 | P21917 | 3/20 | 0.69 |
| ▸ | HRH2 | P25021 | 3/20 | 0.69 |
| ▸ | HTR1B | P28222 | 3/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.69 |
| ▸ | HTR6 | P50406 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9650017 | 0.99 | HTR2B (0.82) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL675164 | 0.91 | HTR2B (1.00) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL30543449 | 0.91 | HTR2B (1.00) | HTR2BHTR2CDRD1HRH1HTR2A | |
| SCHEMBL13337601 | 0.91 | HTR2B (0.84) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL4227186 | 0.91 | HTR2B (1.00) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL29356737 | 0.91 | HTR2B (1.00) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL340674 | 0.91 | HTR2B (1.00) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL13701277 | 0.91 | HTR2B (1.00) | HTR2BHTR2CDRD1HRH1HTR2A | |
| SCHEMBL5794461 | 0.91 | HTR2B (0.84) | HTR2BHTR2CDRD1HRH1HTR2A | |
| Volinanserin SCHEMBL29899671 | 0.90 | HTR2B (0.98) | HTR2BHTR2CDRD1HRH1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644000-A1 | COMPOSITIONS CONTAINING A SEROTONIN SELECTIVE REUPTAKE INHIBITOR AND A 5-HT2A RECEPTOR ANTAGONIST | Pfizer Products Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050070577-A1 | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist | PFIZER INC. | 2005-03-31 | — | — | US | claimed |
| WO-2005002578-A1 | COMPOSITIONS CONTAINING A SEROTONIN SELECTIVE REUPTAKE INHIBITOR AND A 5-HT2A RECEPTOR ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2005-01-13 | — | — | WO | claimed |
| EP-0325063-B1 | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMA (US) | 1994-03-09 | — | — | EP | claimed |
| US-5169096-A | Serotonin antagonists, analgesics | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-12-08 | — | — | US | claimed |
| US-4908369-A | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | claimed |
| EP-1644000-A1 | COMPOSITIONS CONTAINING A SEROTONIN SELECTIVE REUPTAKE INHIBITOR AND A 5-HT2A RECEPTOR ANTAGONIST | Pfizer Products Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070577-A1 | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist | PFIZER INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005002578-A1 | COMPOSITIONS CONTAINING A SEROTONIN SELECTIVE REUPTAKE INHIBITOR AND A 5-HT2A RECEPTOR ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-6004980-A | TEATING DRUG ABUSE, RAYNAUD'S PHENOMENON, EXTRAPYRAMIDAL SYMPTOMS, ANOREXIA, ARRHYTHMIA, ANXIETY, AND FIBROMYALGIA WITH ANTISEROTONIN AGENT OR 5HT2 ANTAGONIST | MERRELL PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5874445-A | ADMINISTERING A THERAPEUTICAL AMOUNT OF (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOREPHENYL) ETHYL)-4-PIPERIDIENEMETHANOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION | MERRELL PHARMACEUTICAL, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| US-5721249-A | ADMINISTERING TO TREAT ANGINA | MERRELL PHARMACEUTICALS INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5700812-A | ANTISPASMODIC AGENT FOR CARDIOVASCULAR DISORDER, ANTISEROTONINE AGENT | MERRELL PHARMACEUTICALS INC. (US) | 1997-12-23 | — | — | US | disclosed |
| US-5021428-A | Novel chemical compounds for the prophylactic treatment of migraine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-06-04 | — | — | US | disclosed |
| US-4912117-A | Therapy for varient angina | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0208235-B1 | N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0337136-A2 | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0325063-A1 | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0319962-A2 | Piperidinyl methanol derivatives for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-06-14 | — | — | EP | disclosed |
| US-4783471-A | N-aralkyl piperidine methanol derivatives and the uses thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070577-A1 | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist | HTR2A, HTR5A, HTR2C | HTR2B 6/4885HTR2C 3/4885DRD1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.